Publication:
Evaluation of Subjects Experiencing Allergic Reactions to Non-Steroidal Anti-Inflammatory Drugs: Clinical Characteristics and Drugs Involved

dc.contributor.authorPérez-Sánchez, Natalia
dc.contributor.authorDoña, Inmaculada
dc.contributor.authorBogas, Gador
dc.contributor.authorSalas, María
dc.contributor.authorTestera, Almudena
dc.contributor.authorCornejo-García, José A.
dc.contributor.authorTorres, María J.
dc.contributor.authoraffiliation[Pérez-Sánchez,N; Doña,I; Bogas,G; Salas,M; Testera,A; Torres, MJ] Allergy Unit, Malaga Regional University Hospital, Malaga, Spain. [Pérez-Sánchez,N; Torres, MJ] Departamento de Medicina, Universidad de Málaga, Malaga, Spain. [Cornejo-García,JA; Torres, MJ] Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, ARADyAL, Malaga, Spain. [Torres, MJ] Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Malaga, Spain.
dc.date.accessioned2024-02-12T19:45:58Z
dc.date.available2024-02-12T19:45:58Z
dc.date.issued2020-04-21
dc.description.abstractNon-steroidal anti-inflammatory drugs (NSAIDs), the most commonly prescribed and consumed medicines worldwide, are the main triggers of drug hypersensitivity reactions (DHRs). The underlying mechanisms of NSAID-DHRs may be related to COX-1 inhibition (cross-hypersensitivity reactions, CRs) or to immunological recognition (selective reactions, SRs), being the latter remarkably less studied. SRs include those usually appearing within the first hour after drug intake (single-NSAID-induced urticaria/angioedema or anaphylaxis, SNIUAA), and those usually occurring more than 24 h after (single-NSAID-induced delayed reactions, SNIDR). We have evaluated the largest series of patients with SRs, analyzing the number of episodes and drugs involved, the latency for reaction onset, the clinical entities, among other variables, as well as the value of available diagnostic methods. Globally, pyrazolones and arylpropionics were the most frequent culprits (39.3% and 37.3%, respectively). Pyrazolones were the most frequent triggers in SNIUAA and arylpropionics in SNIDR. Urticaria was the most common clinical entity in SNIUAA (42.4%) followed by anaphylaxis (33.3%); whereas SNIDR induced mostly fixed drug eruption (41.1%) and maculopapular exanthema (32.6%). The percentage of patients diagnosed by clinical history was higher in SNIUAA compared with SNIDR (62.7% versus 35.3%, p = 0.00015), whereas the percentage of those diagnosed by skin tests was higher in SNIDR than in SNIUAA (47.1% versus 22.8%, p = 0.00015). Drug provocation test with the culprit was performed in 67 SNIUAA (14.5%) and in 9 SNIDR (17.6%) patients. Our results may be of interest not only for allergologists but also for other clinicians dealing with these drugs, and can be useful for the correct identification of subjects experiencing DHRs to NSAIDs, and for avoiding mislabeling. Moreover, as NSAIDs are highly consumed worldwide, our results may be of interest for evaluating other populations exposed to these drugs.
dc.description.sponsorshipThis work was supported by grants co-funded by the European Regional Development Fund (ERDF), from the Carlos III National Health Institute (ARADyAL network RD16/0006/0001, and PI17/01593), and from the Sociedad Española de Alergoloǵıa e Inmunoloǵıa Cĺınica (SEAIC; Ref. Convocatoria Ayudas 2016, and Convocatoria Ayudas 2018 REF: 18B02).
dc.identifier.doi10.3389/fphar.2020.00503
dc.identifier.e-issn1663-9812es_ES
dc.identifier.journalFrontiers in Pharmacologyes_ES
dc.identifier.otherhttp://hdl.handle.net/10668/3513
dc.identifier.pubmedID32425774es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18033
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fphar.2020.00503/fulles
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectDrug allergy
dc.subjectNon-steroidal anti-inflammatory drugs
dc.subjectUrticarial
dc.subjectAnaphylaxis
dc.subjectClinical immunology
dc.subjectHipersensibilidad a las drogas
dc.subjectAntiinflamatorios no esteroideos
dc.subjectUrticaria
dc.subjectAnafilaxia
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal
dc.subject.meshDrug Hypersensitivity
dc.subject.meshUrticaria
dc.subject.meshHypersensitivity
dc.subject.meshAnaphylaxis
dc.subject.meshHumans
dc.subject.meshSpain
dc.subject.meshAngioedema
dc.subject.meshDrug Eruptions
dc.subject.meshPyrazolones
dc.subject.meshPharmaceutical Preparations
dc.subject.meshExanthema
dc.titleEvaluation of Subjects Experiencing Allergic Reactions to Non-Steroidal Anti-Inflammatory Drugs: Clinical Characteristics and Drugs Involved
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isPublisherOfPublication9f9fa5ea-093b-43d8-bf2c-5bd65d08a802
relation.isPublisherOfPublication.latestForDiscovery9f9fa5ea-093b-43d8-bf2c-5bd65d08a802

Files